Head-to-head · WeighScore
Joi + Blokes vs RestorLife Med
The verdict
Joi + Blokes takes it — 66.1/100 to 65.3/100, but only just.
Joi + Blokes grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Joi + Blokes is a hormone-first telehealth platform with parallel programs for women (Joi) and men (Blokes), now expanded to compounded GLP-1s for weight loss. RestorLife Med is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Joi + Blokes | RestorLife Med |
|---|---|---|
| WeighScore | 66.1/100 | 65.3/100 |
| Grade | C | C |
| Scorecard rank | #203 | #222 |
| Semaglutide | $199/mo (promotional rate, quarterly plan, compounded) | $199/mo (6-month plan, compounded) |
| Tirzepatide | $299/mo (quarterly plan, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #203 · C
Strengths
- Separate programs for women (Joi) and men (Blokes) — most GLP-1 telehealth is gender-agnostic
- Trustpilot 4.6/5 from 1,254+ reviews — among the strongest review signals in the category
- Monthly price includes medication, dosing support, clinician consults, and health coaching
- Integrated hormone + GLP-1 programs help patients on testosterone or perimenopausal protocols
- First-month discount ($99 sema / $149 tirz) lowers the barrier to trying GLP-1s
Where it loses points
- Billed quarterly — a 3-month commitment up front, not month-to-month
- Different pricing in NY and NJ — verify your state's cost before committing
- Per-state availability isn't listed; it's zip-code gated behind signup
- Months 2+ cost more ($199 sema / $299 tirz) than the headline intro price
- No FDA-approved Wegovy — compounded only on the GLP-1 side; Zepbound carries a separate visit fee
Graded #222 · C
Strengths
- Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
- Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
- Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
- Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
- Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12
Where it loses points
- The advertised $299 is a struck-through anchor price, not a starting point: the real month-to-month rate is $299, a first month runs $149 at 50% off, and the $199 rate needs six months
- The page states its pricing is 'introductory and subject to change', so none of these figures is committed to
- The tirzepatide price is published the same way, against a struck-through anchor, and we could not establish which figure a buyer actually pays
- A separate semaglutide microdose is sold at $99/mo — a sub-therapeutic protocol, not a cheaper weight-loss dose
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.